Literature DB >> 29336616

Study of the osteoprotegerin/receptor activator of nuclear factor-kB ligand system association with inflammation and atherosclerosis in systemic sclerosis.

Rania M Gamal1, Walid M Gamal2, Abeer M Ghandour1, Hanan Sayed M Abozaid3, Mona Embarek Mohamed4, Yasser Emad5, Ahmed Abdel Galeel6.   

Abstract

OBJECTIVE: we aimed to study systemic sclerosis patients in order to assess osteoprotegerin/Receptor activator of nuclear factor-kB ligand (OPG/RANKL) system and find the relation of these biomarkers with the clinical features of the disease, the carotid intima thickness, markers of inflammation, lipid profile, and other laboratory characteristics.
METHODS: both the level of (RANKL), (OPG) in sera of participants, in 30 (SSc) patients and the atherosclerotic changes affecting the common carotid artery were measured and, were compared to 30 healthy controls matched for age and sex. All participants were assessed clinically and subjected to the Revised Medsger SSc severity scale and underwent carotid Doppler ultrasound examination.
RESULTS: OPG, RANKL, and RANKL/OPG were 1.9 ± 0.4 ng/ml, 24.3 ± 17.25 ng/ml, and 13.5 ±9.8 versus 0.77 ± 0.25 ng/ml, 7.13 ± 3.02 ng/ml, and 9.6 ± 3.1 in the SSc patients and the controls with significance (P = 0.001, P = 0.001, P = 0.045) respectively. The OPG- RANKL axis in the SSc patients correlated significantly with carotid intima thickness, arthritis, arthralgia, inflammatory markers, Medsger joint, Medsger vascular, Medsger skin, and dyslipidemia.
CONCLUSION: In cardiovascular risks, OPG serum level might increase as a preventive compensatory mechanism to neutralize the RANKL level increment. The determination of the OPG-RANKL system is a diagnostic indicator for the intensity of vascular calcification and atherosclerosis in SSc patients.

Entities:  

Keywords:  Atherosclerosis; carotid intima media thickness; receptor activator of nuclear factor-kB ligand System; systemic sclerosis

Mesh:

Substances:

Year:  2018        PMID: 29336616     DOI: 10.1080/08820139.2017.1423499

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Oral manifestations of patients with systemic sclerosis: a meta-analysis for case-controlled studies.

Authors:  Suhan Zhang; Junfei Zhu; Yanshan Zhu; Xiaochao Zhang; Ruifang Wu; Siying Li; Yuwen Su
Journal:  BMC Oral Health       Date:  2021-05-10       Impact factor: 2.757

2.  Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters.

Authors:  Rania M Gamal; Hanan Sayed M Abozaid; Mohmed Zidan; Mohamed Aboel-Kassem F Abdelmegid; Mohmed Raouf Abdel-Razek; Sahar Abdel-Rahman Alsayed; Amr F Mourad; Nashwa Mostafa A Azoz; Lobna Abdel-Wahid Mohram; Daniel E Furst
Journal:  Arthritis Res Ther       Date:  2019-04-15       Impact factor: 5.156

3.  Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.

Authors:  Masahiro Kondo; Tsuyoshi Suzuki; Yuko Kawano; Shinji Kojima; Masahiko Miyashiro; Atsuhiro Matsumoto; Gabriela Kania; Przemysław Błyszczuk; Rebecca L Ross; Panji Mulipa; Francesco Del Galdo; Yun Zhang; Jörg H W Distler
Journal:  Arthritis Res Ther       Date:  2022-09-01       Impact factor: 5.606

Review 4.  α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Authors:  Yosuke Kanno; En Shu
Journal:  Life (Basel)       Date:  2022-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.